Amarant Pharmaceuticals Private Limited
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi-based pharmaceutical manufacturer with pharmaceutical and nutraceutical portfolios, quality, regulatory and export functions.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Amarant Pharmaceuticals (Private) Limited
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot #168, Sector 23, Korangi Industrial Area, Karachi, Pakistan
- Website
- amarantpharma.com ↗
- Phone
- +92 21 35121361-63
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Amarant Pharmaceuticals Private Limited is priced against the market
127 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Cyclorant | Cycloserine | 250 mg | Capsule | 10's | 076131 | PKR 1,491.16 | PKR 149.12/capsule | 🔒 Pharma Pro |
| Deprion SR | Bupropion | 150 mg | Sustained-release tablet | 10's | 067009 | PKR 311.20 | PKR 31.12/tablet | 🔒 Pharma Pro |
| Deprion SR | Bupropion | 300 mg | Sustained-release tablet | 30's | 067386 | PKR 2,607.37 | PKR 86.91/tablet | 🔒 Pharma Pro |
| Deprion SR | Bupropion | 300 mg | Sustained-release tablet | 10’s | 067386 | PKR 944.71 | PKR 94.47/tablet | 🔒 Pharma Pro |
| Deprion SR | Bupropion | 300 mg | Sustained-release tablet | 20's | 067386 | PKR 1,789.38 | PKR 89.47/tablet | 🔒 Pharma Pro |
| Dipodium | Sodium valproate | 250 mg/5 mL | Syrup | 60mL | 058619 | PKR 110.02 | PKR 1.83/mL | 🔒 Pharma Pro |
| Dipodium | Sodium valproate | 250 mg/5 mL | Syrup | 120mL | 058619 | PKR 220.04 | PKR 1.83/mL | 🔒 Pharma Pro |
| Dipodium | Divalproex sodium | 250 mg | Tablet | 10 X10's | 058620 | PKR 847.74 | PKR 8.48/tablet | 🔒 Pharma Pro |
| Dipodium | Sodium valproate | 500 mg/5 mL | Syrup | 60 mL | 058622 | PKR 171.42 | PKR 2.86/mL | No comparator |
| Dipodium DS | Divalproex sodium | 500 mg | Tablet | 30's | 058621 | PKR 405.34 | PKR 13.51/tablet | 🔒 Pharma Pro |
| Dipodium DS | Divalproex sodium | 500 mg | Tablet | 10 x 10's | 058621 | PKR 1,323.73 | PKR 13.24/tablet | 🔒 Pharma Pro |
| Edper | Permethrin | 5% | Cream | 30 gm | 067013 | PKR 82.61 | PKR 2.75/g | 🔒 Pharma Pro |
| Edtac Ointment | Tacrolimus | 1 mg | Ointment | 10gm | 067016 | PKR 333.42 | PKR 33.34/g | No comparator |
| Emess Injection 40mg (IV)Registry verified | Esomeprazole (as Sodium) | — | — | — | 131051Official source ↗ | No indexed price | — | — |
| Feriant | Iron protein succinylate | 800 mg/15 mL (equiv. 40 mg elemental iron) | Syrup | 120 mL | 042046 | PKR 356.22 | PKR 2.97/mL | 🔒 Pharma Pro |
| Feriant | Iron protein succinylate | 800 mg/5 mL | Syrup | 60 mL | 042046 | PKR 186.96 | PKR 3.12/mL | 🔒 Pharma Pro |
| Flow Lactate-DSource observed | Ringer's lactate solution + Dextrose | NaCl 0.6g + KCl 0.03g + CaCl2 0.02g + Na lactate 0.31g + Dextrose 5.0g/100 mL | IV infusion | 500 mL | 089079Official source ↗ | No indexed price | — | — |
| Floxicon | Ofloxacin | 200 mg | Tablet | 10’s | 042071 | PKR 237.52 | PKR 23.75/tablet | 🔒 Pharma Pro |
| Floxicon | Ofloxacin | 400 mg | Tablet | 10’s | 042072 | PKR 309.80 | PKR 30.98/tablet | 🔒 Pharma Pro |
| Fludine | Loratadine | 10 mg | Tablet | 10’s | 042036 | PKR 137.65 | PKR 13.77/tablet | 🔒 Pharma Pro |
| Getex | Cefotaxime | 250 mg | Dry powder for injection | 1's | 080277 | PKR 105.47 | PKR 105.47/vial/unit | 🔒 Pharma Pro |
| Getex | Cefotaxime | 500 mg | Dry powder for injection | 1's | 080278 | PKR 158.95 | PKR 158.95/vial/unit | 🔒 Pharma Pro |
| Getex | Cefotaxime | 1 g | Dry powder for injection | 1's | 080279 | PKR 285.88 | PKR 285.88/vial/unit | 🔒 Pharma Pro |
| Habrin | Ribavirin | 200 mg | Capsule | 10’s | 042099 | PKR 495.67 | PKR 49.57/capsule | 🔒 Pharma Pro |
| Habrin | Ribavirin | 400 mg | Capsule | 10’s | 042100 | PKR 619.58 | PKR 61.96/capsule | 🔒 Pharma Pro |
| Hemosoft | Iron polymaltose complex | 100 mg | Tablet | 10’s | 042043 | PKR 137.77 | PKR 13.78/tablet | 🔒 Pharma Pro |
| Hemosoft | Iron polymaltose complex | 50 mg/5 mL | Syrup | 60mL | 042045 | PKR 137.77 | PKR 2.30/mL | 🔒 Pharma Pro |
| Hemosoft-F | Iron polymaltose complex | 100 mg | Tablet | 10's | 042044 | PKR 144.58 | PKR 14.46/tablet | 🔒 Pharma Pro |
| Hysim-E | Ezetimibe + Simvastatin | 10 mg + 10 mg | Tablet | 7's | 057790 | PKR 722.86 | PKR 103.27/tablet | 🔒 Pharma Pro |
| Hysim-E | Ezetimibe + Simvastatin | 20 mg + 20 mg | Tablet | 7's | 057791 | PKR 1,012.00 | PKR 144.57/tablet | No comparator |
| Ibulexin | Ibuprofen | 200 mg | Tablet | 10 x 10's | 042031 | PKR 250.99 | PKR 2.51/tablet | 🔒 Pharma Pro |
| IbulexinSource observed | Ibuprofen | 100 mg | Held for normalizationSource reported: Tablet · structural field conflict | 90ml | 042032Official source ↗ | No indexed price | — | — |
| Lexazole | Metronidazole | 200 mg | Tablet | 30’s | 042053 | PKR 113.25 | PKR 3.78/tablet | 🔒 Pharma Pro |
| Lexazole | Metronidazole (Benzoate) | 200 mg/5 mL | Suspension | 60ml | 042055 | PKR 62.93 | PKR 1.05/mL | 🔒 Pharma Pro |
| Lexazole DS | Metronidazole + Diloxanide furoate | 400 mg + 500 mg | Tablet | 15’s | 042054 | PKR 92.94 | PKR 6.20/tablet | 🔒 Pharma Pro |
| Lexidox | Doxycycline | 100 mg | Tablet | 30's | 042052 | PKR 216.87 | PKR 7.23/tablet | 🔒 Pharma Pro |
| Lexidox | Doxycycline | 100 mg | Tablet | 100's | 042052 | PKR 702.20 | PKR 7.02/tablet | 🔒 Pharma Pro |
| Lexitran | Sulfamethoxazole + Trimethoprim | 80 mg + 400 mg | Tablet | 400's | 042058 | PKR 1,195.49 | PKR 2.99/tablet | 🔒 Pharma Pro |
| Lignorant | Lidocaine | 2% w/w | Gel | 15g | 042093 | PKR 37.06 | PKR 2.47/g | No comparator |
| Limgit | Lamotrigine = | 50 mg | Tablet | 3×10’s | 075883 | PKR 864.88 | PKR 28.83/tablet | 🔒 Pharma Pro |
| Limgit | Lamotrigine = | 25 mg | Tablet | 3×10’s | 075885 | PKR 648.65 | PKR 21.62/tablet | 🔒 Pharma Pro |
| Limgit | Lamotrigine = | 100 mg | Tablet | 3×10’s | 075886 | PKR 1,081.10 | PKR 36.04/tablet | 🔒 Pharma Pro |
| Listan AH | Amlodipine + Valsartan + Hydrochlorothiazide | 10 mg + 160 mg + 25 mg | Tablet | 14's | 098552 | PKR 255.71 | PKR 18.27/tablet | 🔒 Pharma Pro |
| Listan AH | Amlodipine | 10 mg | Tablet | 28's | 098552 | PKR 511.44 | PKR 18.27/tablet | 🔒 Pharma Pro |
| Listan AH | Amlodipine + Valsartan + Hydrochlorothiazide | 5 mg + 160 mg + 25 mg | Tablet | 14's | 098553 | PKR 238.85 | PKR 17.06/tablet | 🔒 Pharma Pro |
| Listan AH | Amlodipine | 5 mg | Tablet | 28's | 098553 | PKR 477.71 | PKR 17.06/tablet | 🔒 Pharma Pro |
| Listan AH | Amlodipine + Valsartan + Hydrochlorothiazide | 10 mg + 320 mg + 25 mg | Tablet | 14's | 098554 | PKR 393.40 | PKR 28.10/tablet | 🔒 Pharma Pro |
| Listan AH | Amlodipine + Valsartan + Hydrochlorothiazide | 5 mg + 160 mg + 12.5 mg | Tablet | 14's | 098555 | PKR 233.23 | PKR 16.66/tablet | 🔒 Pharma Pro |
| Listan AH | Amlodipine | 5 mg | Tablet | 28's | 098555 | PKR 466.47 | PKR 16.66/tablet | 🔒 Pharma Pro |
| Listan AH | Amlodipine + Valsartan + Hydrochlorothiazide | 10 mg + 160 mg + 12.5 mg | Tablet | 14's | 098556 | PKR 252.91 | PKR 18.07/tablet | 🔒 Pharma Pro |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.